Purple Biotech (PPBT)

Executive Summary

Purple Biotech Ltd. (NASDAQ: PPBT) is a clinical-stage oncology biotechnology company headquartered in Rehovot, Israel. The company focuses on developing therapies that counteract tumor immune evasion and drug resistance. Its lead candidate, CM24, is a monoclonal antibody targeting CEACAM1, an immune checkpoint protein. CM24 is currently being evaluated in a Phase 2 study in combination with nivolumab (Opdivo®) for non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The second clinical asset, NT219, is a dual inhibitor of IRS1/2 and STAT3, key signaling nodes implicated in resistance to multiple anticancer therapies. NT219 is in Phase 1/2 development for recurrent and metastatic solid tumors, including head and neck squamous cell carcinoma. The company’s pipeline aims to address significant unmet needs in oncology, and its clinical programs are progressing based on preclinical and early clinical evidence of target engagement and activity. As a publicly traded entity, Purple Biotech continues to advance its research and development efforts from its Israeli operations, with a strategic focus on generating clinical data to support the further development of its therapeutic candidates in specific oncology indications. The company’s ability to execute on its clinical milestones and secure additional funding will be critical for its near-term progress and value creation. With a market valuation of approximately $6 million, Purple Biotech represents a high-risk, high-potential opportunity in the oncology space, pending data readouts and potential partnership discussions.

Upcoming Catalysts (preview)

• H2 2026CM24 Phase 2 interim data in NSCLC or PDAC60% success
• Q3 2026NT219 Phase 1/2 dose escalation and preliminary efficacy data55% success
• H2 2026Potential partnership or licensing deal for CM2430% success